Stock A185490 EYEGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company EyeGene Inc.

Equities

A185490

KR7185490000

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3,110 KRW -.--% Intraday chart for EyeGene Inc. -4.01% -27.08%
2023 EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd. CI
2023 EyeGene Inc. announced that it expects to receive KRW 15.000001688 billion in funding from BMI Korea Co., Ltd. CI

Business Summary

EyeGene, Inc. is a Korea-based company mainly engaged in the development of therapeutics, diagnostics, and technologies for eye-related diseases. The Company’s products consist of EG-Mirotin, which is a therapeutics of ocular angiogenesis of the diagnostic of early-stage of diabetic retinopathy (DR) and retinopathy of prematurity (ROP); EG-Decorin, a topical ointment for pressure ulcer and diabetic foot ulcer; EG-HPV, a human papillomavirus vaccine; EGS, a scarless wound repair agent, and EG-Vac, a novel vaccine adjuvant for various vaccine preparations.

Sales per Business

KRW in Million2022Weight2023Weight Delta
Pharmaceutical Products
69.5 %
3,437 64.9 % 2,172 69.5 % -36.82%
Technology
30.4 %
1,833 34.6 % 950 30.4 % -48.17%
Service
0.1 %
19 0.4 % 3 0.1 % -84.36%
Other
0.0 %
4 0.1 % 0 0.0 % -87.18%

Sales per region

KRW in Million2022Weight2023Weight Delta
South Korea
100.0 %
5,293 100.0 % 3,125 100.0 % -40.96%

Managers

Managers TitleAgeSince
Won-Il Yoo CEO
 Chief Executive Officer 60 00-06-22
Myeong-Jae Rhee DFI
 Director of Finance/CFO 54 12-04-30
Yang-Je Cho CTO
 Chief Tech/Sci/R&D Officer 56 00-06-22
Jong-Doo Choi AUD
 Comptroller/Controller/Auditor 55 12-02-29

Members of the board

Members of the board TitleAgeSince
Jong-Doo Choi AUD
 Comptroller/Controller/Auditor 55 12-02-29
Won-Il Yoo CEO
 Chief Executive Officer 60 00-06-22
Yang-Je Cho CTO
 Chief Tech/Sci/R&D Officer 56 00-06-22
Dal-Hyun Kim BRD
 Director/Board Member 62 -
Doo-Sik Kim BRD
 Director/Board Member 73 15-02-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 27,029,784 19,457,203 ( 71.98 %) 0 71.98 %

Shareholders

NameEquities%Valuation
BMI Korea Co., Ltd.
21.48 %
5,805,137 21.48 % 15 M ₩
Won-Il Yoo
4.813 %
1,300,946 4.813 % 3 M ₩
Gu Woo
1.199 %
324,192 1.199 % 816 351 ₩
Myeong-Jae Rhee
0.2369 %
64,022 0.2369 % 161 214 ₩
Hyung-soo Yoon
0.1627 %
43,984 0.1627 % 110 757 ₩
Doo-Sik Kim
0.1110 %
30,000 0.1110 % 75 543 ₩
Kwang-in Lee
0.0826 %
22,316 0.0826 % 56 194 ₩
Suk-Keun Choi
0.0373 %
10,087 0.0373 % 25 400 ₩
Hyun-ki Kim
0.0166 %
4,500 0.0166 % 11 331 ₩

Company contact information

EyeGene, Inc.

B-1211 401 Yangcheon-ro

07528, Seoul

+

http://www.eyegene.co.kr
address EyeGene Inc.(A185490)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sector Other Pharmaceuticals

1st Jan change Capi.
EYEGENE INC. Stock EyeGene Inc.
-27.08% 60.75M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 699B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.71% 571B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 326B
ABBVIE INC. Stock AbbVie Inc.
+4.36% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.47% 236B
NOVARTIS AG Stock Novartis AG
+5.26% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-10.02% 194B
AMGEN INC. Stock Amgen Inc.
-3.69% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A185490 Stock
  4. Company EyeGene Inc.